Pablo Jimenez Labaig, Medical Oncologist at The Royal Marsden NHS Fundation Trust, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Just published the full manuscript about our meta-analyses on second-event endpoints (EFS2/PRFS2/PFS2) in antiPD(L)1 trials in ImmunoTherapy of Cancer
47 RCTs. 34,973 patients
In meta-regressions, prior AntiPD(L)1s exposition reduced/delayed subsequent PD events compared with IO-naïve patients
Strong correlation with OS, higher than first-event endpoints (EFS/DFS/PFS) as expected. Now represented
A pleasure having work alongside Oriol Mirallas, Ana Isabel Martin Quesada, Toni Rullan, Dario Trapani, Teresa Amaral, Enriqueta Felip, Josep Tabernero, Kevin Harrington.”
Title: Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis
Authors: Pablo Jimenez, Oriol Mirallas, Ana Martin Quesada, Antonio Rullan, Dario Trapani, Teresa Amaral, Enriqueta Felip, Josep Tabernero, Kevin J. Harrington
Read the Full Article on Journal for ImmunoTherapy of Cancer
More posts featuring Pablo Jimenez Labaig.
